These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

109 related articles for article (PubMed ID: 16741919)

  • 21. Effects of serum PSA on efficacy of tolterodine extended release with or without tamsulosin in men with LUTS, including OAB.
    Roehrborn CG; Kaplan SA; Kraus SR; Wang JT; Bavendam T; Guan Z
    Urology; 2008 Nov; 72(5):1061-7; discussion 1067. PubMed ID: 18817961
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Prostate-specific antigen velocity and prostate cancer gleason grade and stage.
    Pinsky PF; Andriole G; Crawford ED; Chia D; Kramer BS; Grubb R; Greenlee R; Gohagan JK
    Cancer; 2007 Apr; 109(8):1689-95. PubMed ID: 17330856
    [TBL] [Abstract][Full Text] [Related]  

  • 23. [Rebound of prostate specific antigen after discontinuation of antiandrogen therapy for benign prostatic hyperplasia].
    Noguchi K; Uemura H; Takeda M; Sekiguchi Y; Ogawa K; Hosaka M
    Hinyokika Kiyo; 2000 Sep; 46(9):605-7. PubMed ID: 11107528
    [TBL] [Abstract][Full Text] [Related]  

  • 24. BPH progression: concept and key learning from MTOPS, ALTESS, COMBAT, and ALF-ONE.
    Roehrborn CG
    BJU Int; 2008 Mar; 101 Suppl 3():17-21. PubMed ID: 18307681
    [TBL] [Abstract][Full Text] [Related]  

  • 25. A population based study of incidence and treatment of benign prostatic hyperplasia among residents of Olmsted County, Minnesota: 1987 to 1997.
    Sarma AV; Jacobson DJ; McGree ME; Roberts RO; Lieber MM; Jacobsen SJ
    J Urol; 2005 Jun; 173(6):2048-53. PubMed ID: 15879823
    [TBL] [Abstract][Full Text] [Related]  

  • 26. The utility of prostate-specific antigen velocity thresholds in clinical practice: a population-based analysis.
    Connolly D; Black A; Murray LJ; Nambirajan T; Keane PF; Gavin A
    BJU Int; 2008 Jun; 101(12):1507-12. PubMed ID: 18341627
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Recovery of serum prostate specific antigen value after interruption of antiandrogen therapy with allylestrenol for benign prostatic hyperplasia.
    Noguchi K; Suzuki K; Teranishi J; Kondo K; Kishida T; Saito K; Uemura H; Kubota Y
    Hinyokika Kiyo; 2006 Jul; 52(7):527-30. PubMed ID: 16910584
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Prostate-specific antigen changes as a result of chlormadinone acetate administration to patients with benign prostatic hyperplasia: a retrospective multi-institutional study.
    Fujimoto K; Hirao Y; Masumori N; Arai Y; Yamanaka H; Kato T; Miyazawa K
    Int J Urol; 2006 May; 13(5):543-9. PubMed ID: 16771723
    [TBL] [Abstract][Full Text] [Related]  

  • 29. The influence of serial prostate-specific antigen (PSA) screening on the PSA velocity at diagnosis.
    Martin NE; Chen MH; Catalona WJ; Loeb S; Roehl KA; D'Amico AV
    Cancer; 2008 Aug; 113(4):717-22. PubMed ID: 18615505
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Alfuzosin 10 mg once daily for treating benign prostatic hyperplasia: a 3-year experience in real-life practice.
    Vallancien G; Emberton M; Alcaraz A; Matzkin H; van Moorselaar RJ; Hartung R; Harving N; Elhilali M;
    BJU Int; 2008 Apr; 101(7):847-52. PubMed ID: 18321317
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Pretreatment PSA velocity as a predictor of disease outcome following radical radiation therapy.
    Palma D; Tyldesley S; Blood P; Liu M; Morris J; Pickles T;
    Int J Radiat Oncol Biol Phys; 2007 Apr; 67(5):1425-9. PubMed ID: 17394943
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Effect of definition of preradiotherapy prostate-specific antigen velocity on its association with prostate cancer-specific mortality and all-cause mortality.
    Nguyen PL; Chen MH; Renshaw AA; Sussman B; D'Amico AV
    Urology; 2007 Aug; 70(2):288-93. PubMed ID: 17826491
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Baseline factors as predictors of clinical progression of benign prostatic hyperplasia in men treated with placebo.
    Crawford ED; Wilson SS; McConnell JD; Slawin KM; Lieber MC; Smith JA; Meehan AG; Bautista OM; Noble WR; Kusek JW; Nyberg LM; Roehrborn CG;
    J Urol; 2006 Apr; 175(4):1422-6; discussion 1426-7. PubMed ID: 16516013
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Incontinence related to management of benign prostatic hypertrophy.
    Han E; Black LK; Lavelle JP
    Am J Geriatr Pharmacother; 2007 Dec; 5(4):324-34. PubMed ID: 18179990
    [TBL] [Abstract][Full Text] [Related]  

  • 35. The utility of serum prostatic-specific antigen in the management of men with benign prostatic hyperplasia.
    Roehrborn CG
    Int J Impot Res; 2008 Dec; 20 Suppl 3():S19-26. PubMed ID: 19002120
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Postoperative prostate-specific antigen velocity independently predicts for failure of salvage radiotherapy after prostatectomy.
    King CR; Presti JC; Brooks JD; Gill H; Spiotto MT
    Int J Radiat Oncol Biol Phys; 2008 Apr; 70(5):1472-7. PubMed ID: 17935902
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Polymorphisms in the alpha1A-adrenoceptor gene do not modify the short- and long-term efficacy of alpha1-adrenoceptor antagonists in the treatment of benign prostatic hyperplasia.
    Mochtar CA; Laan W; Van Houwelingen KP; Franke B; De La Rosette JJ; Schalken JA; Kiemeney LA
    BJU Int; 2006 Apr; 97(4):852-5. PubMed ID: 16536786
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Absolute prostate-specific antigen value after androgen deprivation is a strong independent predictor of survival in new metastatic prostate cancer: data from Southwest Oncology Group Trial 9346 (INT-0162).
    Hussain M; Tangen CM; Higano C; Schelhammer PF; Faulkner J; Crawford ED; Wilding G; Akdas A; Small EJ; Donnelly B; MacVicar G; Raghavan D;
    J Clin Oncol; 2006 Aug; 24(24):3984-90. PubMed ID: 16921051
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Relapse after radical prostatectomy correlates with preoperative PSA velocity and tumor volume: results from a screening population.
    Berger AP; Deibl M; Strasak A; Bektic J; Pelzer A; Steiner H; Spranger R; Fritsche G; Bartsch G; Horninger W
    Urology; 2006 Nov; 68(5):1067-71. PubMed ID: 17095070
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Analysis of prostate-specific antigen bounce after I(125) permanent seed implant for localised prostate cancer.
    Mitchell DM; Swindell R; Elliott T; Wylie JP; Taylor CM; Logue JP
    Radiother Oncol; 2008 Jul; 88(1):102-7. PubMed ID: 18453022
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.